CN1073103C - 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 - Google Patents
用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 Download PDFInfo
- Publication number
- CN1073103C CN1073103C CN97196877A CN97196877A CN1073103C CN 1073103 C CN1073103 C CN 1073103C CN 97196877 A CN97196877 A CN 97196877A CN 97196877 A CN97196877 A CN 97196877A CN 1073103 C CN1073103 C CN 1073103C
- Authority
- CN
- China
- Prior art keywords
- base
- compound
- alkylidene group
- inferior
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2313996P | 1996-07-30 | 1996-07-30 | |
US60/023,139 | 1996-07-30 | ||
US89577297A | 1997-07-17 | 1997-07-17 | |
US08/895,772 | 1997-07-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1226892A CN1226892A (zh) | 1999-08-25 |
CN1073103C true CN1073103C (zh) | 2001-10-17 |
Family
ID=26696778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97196877A Expired - Fee Related CN1073103C (zh) | 1996-07-30 | 1997-07-30 | 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0934293A1 (sv) |
JP (1) | JP2001509787A (sv) |
KR (1) | KR20000029679A (sv) |
CN (1) | CN1073103C (sv) |
AU (1) | AU733621B2 (sv) |
CA (1) | CA2262542A1 (sv) |
CZ (1) | CZ29799A3 (sv) |
EE (1) | EE9900036A (sv) |
FI (1) | FI990171A (sv) |
HU (1) | HUP0003267A3 (sv) |
LV (1) | LV12291B (sv) |
NO (1) | NO990433L (sv) |
NZ (1) | NZ333713A (sv) |
PL (1) | PL331465A1 (sv) |
SI (1) | SI9720047A (sv) |
SK (1) | SK8599A3 (sv) |
WO (1) | WO1998004537A1 (sv) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
WO1999040083A2 (de) * | 1998-02-06 | 1999-08-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Bifunktionelle tryptase-inhibitoren |
US6613769B1 (en) * | 1998-02-06 | 2003-09-02 | Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. | Tryptase inhibitors |
WO2000014097A2 (de) * | 1998-09-04 | 2000-03-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyranosen |
ATE279398T1 (de) | 1999-08-10 | 2004-10-15 | Altana Pharma Ag | Diazocindionderivate und ihre verwendung als tryptase inhibitoren |
US6960588B1 (en) | 1999-09-14 | 2005-11-01 | Altana Pharma Ag | Tryptase inhibitors |
AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
DE19955476A1 (de) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US6815557B2 (en) | 1999-12-20 | 2004-11-09 | Altana Pharma Ag | Tryptase inhibitors |
US7015325B2 (en) * | 1999-12-20 | 2006-03-21 | Altana Pharma Ag | Tryptase inhibitors |
WO2002060895A1 (en) * | 2001-01-31 | 2002-08-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Diazocine derivatives and their use as tryptase inhibitors |
ES2287268T3 (es) | 2001-02-21 | 2007-12-16 | Nycomed Gmbh | Inhibidores de triptasa. |
ATE349427T1 (de) | 2001-02-21 | 2007-01-15 | Altana Pharma Ag | Tryptaseinhibitoren |
JP2004525926A (ja) * | 2001-03-15 | 2004-08-26 | アルタナ ファルマ アクチエンゲゼルシャフト | トリプターゼ阻害剤 |
WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100392A1 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
WO2002102771A1 (en) | 2001-06-19 | 2002-12-27 | Altana Pharma Ag | Tryptase inhibitors |
US8795725B2 (en) | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類 |
KR101335118B1 (ko) * | 2008-12-19 | 2013-12-05 | 메르츠 파마 게엠베하 운트 코. 카가아 | 비만 세포 매개 질환의 치료를 위한 1-아미노-알킬시클로헥산 유도체 |
FR3038605B1 (fr) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation |
US20200199168A1 (en) * | 2017-05-12 | 2020-06-25 | Riken | Class a gpcr-binding compound modifier |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032945A1 (en) * | 1994-06-01 | 1995-12-07 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
WO1996009297A1 (en) * | 1994-09-23 | 1996-03-28 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell inflammatory condition |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
EP0688337A1 (en) * | 1993-03-12 | 1995-12-27 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
CN1071751C (zh) * | 1995-03-24 | 2001-09-26 | 阿克西斯制药公司 | 可逆蛋白酶抑制剂 |
TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 PL PL97331465A patent/PL331465A1/xx unknown
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/ko not_active Application Discontinuation
- 1997-07-30 SK SK85-99A patent/SK8599A3/sk unknown
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 CN CN97196877A patent/CN1073103C/zh not_active Expired - Fee Related
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/cs unknown
- 1997-07-30 NZ NZ333713A patent/NZ333713A/xx unknown
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/hu unknown
- 1997-07-30 JP JP50913698A patent/JP2001509787A/ja active Pending
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 SI SI9720047A patent/SI9720047A/sl unknown
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
- 1997-07-30 EE EEP199900036A patent/EE9900036A/xx unknown
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/no not_active Application Discontinuation
- 1999-01-29 FI FI990171A patent/FI990171A/sv unknown
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995032945A1 (en) * | 1994-06-01 | 1995-12-07 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
WO1996009297A1 (en) * | 1994-09-23 | 1996-03-28 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell inflammatory condition |
Also Published As
Publication number | Publication date |
---|---|
NZ333713A (en) | 2000-12-22 |
EP0934293A1 (en) | 1999-08-11 |
HUP0003267A2 (hu) | 2001-06-28 |
FI990171A0 (sv) | 1999-01-29 |
FI990171A (sv) | 1999-03-23 |
PL331465A1 (en) | 1999-07-19 |
EE9900036A (et) | 1999-08-16 |
KR20000029679A (ko) | 2000-05-25 |
JP2001509787A (ja) | 2001-07-24 |
SI9720047A (sl) | 1999-08-31 |
AU733621B2 (en) | 2001-05-17 |
CA2262542A1 (en) | 1998-02-05 |
HUP0003267A3 (en) | 2002-02-28 |
WO1998004537A1 (en) | 1998-02-05 |
AU3967097A (en) | 1998-02-20 |
LV12291B (en) | 2000-04-20 |
SK8599A3 (en) | 2000-03-13 |
NO990433L (no) | 1999-03-25 |
CZ29799A3 (cs) | 1999-06-16 |
LV12291A (lv) | 1999-06-20 |
CN1226892A (zh) | 1999-08-25 |
NO990433D0 (no) | 1999-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1073103C (zh) | 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 | |
CN1143855C (zh) | 作为抗凝剂的邻氨基苯甲酰胺衍生物 | |
CN1107061C (zh) | 趋化细胞因子受体-3拮抗剂 | |
CN1077573C (zh) | 用作神经激肽拮抗剂的杂环类化合物 | |
CN1036918C (zh) | 苯并吡喃衍生物及含有此衍生物的k+通道活化剂 | |
CN1207056C (zh) | 含肽的α-酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂 | |
CN1329596A (zh) | 吡啶甲酰胺衍生物、含有其作为有效成分的有害生物防除剂 | |
CN1115982A (zh) | 具有药理学活性的吡啶类衍生物及其制备方法 | |
CN1254337A (zh) | N-羟基4-磺酰基丁酰胺化合物 | |
CN1040986A (zh) | 环烷基取代的戊二酰胺衍生物的制备 | |
CN1088917A (zh) | 取代的苄氨基含氮非芳族杂环化合物 | |
CN1431999A (zh) | 具有血管损伤活性的吲哚衍生物 | |
CN1330637A (zh) | 用于治疗炎性疾病的化合物 | |
CN1098094A (zh) | 芳基取代的杂环 | |
CN1871244A (zh) | 作为腺苷受体配体的噻唑并吡啶衍生物 | |
CN1688555A (zh) | 新的二环类激素敏感性脂酶抑制剂 | |
CN1253555A (zh) | 新的2-(亚氨基甲基)氨基-苯基衍生物,其制备方法、作为药物的应用及其药物组合物 | |
CN1198827C (zh) | 精选的K-252a衍生物 | |
CN1278790A (zh) | 化合物 | |
CN1211232A (zh) | 用氨基酸和羟基酸衍生物取代的苄脒衍生物和其作为抗凝血剂的用途 | |
CN1658877A (zh) | 碱性非肽缓激肽拮抗剂及其药物组合物 | |
CN1150162C (zh) | 联苯基脒衍生物 | |
CN1181069A (zh) | 作为速激肽受体拮抗剂的5-(4-取代的哌啶基-1)-3-芳基戊酸衍生物 | |
CN1753891A (zh) | Ccr-3受体拮抗剂 | |
CN1458922A (zh) | 尿素衍生物及以其作为有效成分的粘连分子阻断剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: AXYS PHARMACEUTICAL CORPORATION Free format text: FORMER NAME OR ADDRESS: ARRIS PHARMACEUTICAL CORPORATION |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: AXYS Pharmaceuticals, Inc. Patentee before: Arris Pharmaceutical Corp. |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |